Reviewing Aeglea BioTherapeutics Inc. (AGLE)’s and Molecular Templates Inc. (NASDAQ:MTEM)’s results

Both Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) and Molecular Templates Inc. (NASDAQ:MTEM) are Biotechnology companies, competing one another. We will compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aeglea BioTherapeutics Inc. 3.89M 54.85 44.35M -1.88 0.00
Molecular Templates Inc. 13.29M 18.44 30.29M -1.13 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Aeglea BioTherapeutics Inc. and Molecular Templates Inc.


Table 2 shows us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Aeglea BioTherapeutics Inc. -1,140.10% -62.1% -56%
Molecular Templates Inc. -227.92% -38.6% -29.9%


The Current Ratio and Quick Ratio of Aeglea BioTherapeutics Inc. are 9.4 and 9.4 respectively. Its competitor Molecular Templates Inc.’s Current Ratio is 2.8 and its Quick Ratio is 2.8. Aeglea BioTherapeutics Inc. can pay off short and long-term obligations better than Molecular Templates Inc.

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Aeglea BioTherapeutics Inc. and Molecular Templates Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aeglea BioTherapeutics Inc. 0 0 1 3.00
Molecular Templates Inc. 0 0 0 0.00

Aeglea BioTherapeutics Inc.’s upside potential currently stands at 89.19% and an $14 consensus target price.

Institutional & Insider Ownership

The shares of both Aeglea BioTherapeutics Inc. and Molecular Templates Inc. are owned by institutional investors at 75.3% and 73% respectively. About 1.1% of Aeglea BioTherapeutics Inc.’s share are held by insiders. Comparatively, insiders own roughly 0.7% of Molecular Templates Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aeglea BioTherapeutics Inc. -0.35% -7% -1.16% -21.22% 23.91% 13.48%
Molecular Templates Inc. -9.52% 0.21% -1.25% -13.64% -47.97% 17.57%

For the past year Aeglea BioTherapeutics Inc.’s stock price has smaller growth than Molecular Templates Inc.


Molecular Templates Inc. beats Aeglea BioTherapeutics Inc. on 8 of the 11 factors.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.